HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintains a $36 price target.
May 07, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Pliant Therapeutics with a $36 price target.
The reiteration of a Buy rating and maintenance of a $36 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Pliant Therapeutics. This endorsement may lead to increased investor confidence in PLRX, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100